Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.

Schirinzi T, Martella G, D'Elia A, Di Lazzaro G, Imbriani P, Madeo G, Monaco L, Maltese M, Pisani A.

Parkinsons Dis. 2016;2016:9646057. doi: 10.1155/2016/9646057. Epub 2016 Aug 29.

2.

Smoking-Relevant Nicotine Concentration Attenuates the Unfolded Protein Response in Dopaminergic Neurons.

Srinivasan R, Henley BM, Henderson BJ, Indersmitten T, Cohen BN, Kim CH, McKinney S, Deshpande P, Xiao C, Lester HA.

J Neurosci. 2016 Jan 6;36(1):65-79. doi: 10.1523/JNEUROSCI.2126-15.2016.

3.

Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides.

Ratner MH, Farb DH, Ozer J, Feldman RG, Durso R.

Interdiscip Toxicol. 2014 Sep;7(3):123-33. doi: 10.2478/intox-2014-0017. Epub 2014 Dec 30.

4.

Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.

Quik M, Zhang D, McGregor M, Bordia T.

Biochem Pharmacol. 2015 Oct 15;97(4):399-407. doi: 10.1016/j.bcp.2015.06.014. Epub 2015 Jun 18. Review.

5.

Pentameric Ligand-gated Ion Channels : Insights from Computation.

Salari R, Murlidaran S, Brannigan G.

Mol Simul. 2014 Apr 17;40(10-11):821-829.

6.

Inside-out neuropharmacology of nicotinic drugs.

Henderson BJ, Lester HA.

Neuropharmacology. 2015 Sep;96(Pt B):178-93. doi: 10.1016/j.neuropharm.2015.01.022. Epub 2015 Feb 4. Review.

7.

Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease.

Ritz B, Lee PC, Lassen CF, Arah OA.

Neurology. 2014 Oct 14;83(16):1396-402. doi: 10.1212/WNL.0000000000000879. Epub 2014 Sep 12.

8.

A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking.

van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, van Laar T, Kromhout H, Vermeulen R.

PLoS One. 2014 Apr 30;9(4):e95297. doi: 10.1371/journal.pone.0095297. eCollection 2014.

9.

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Sanders LH, Greenamyre JT.

Free Radic Biol Med. 2013 Sep;62:111-20. doi: 10.1016/j.freeradbiomed.2013.01.003. Epub 2013 Jan 15. Review.

10.

Meta-analysis of early nonmotor features and risk factors for Parkinson disease.

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A.

Ann Neurol. 2012 Dec;72(6):893-901. doi: 10.1002/ana.23687. Epub 2012 Oct 15. Review.

11.

Smoking and risk of skin cancer: a prospective analysis and a meta-analysis.

Song F, Qureshi AA, Gao X, Li T, Han J.

Int J Epidemiol. 2012 Dec;41(6):1694-705. doi: 10.1093/ije/dys146. Epub 2012 Oct 11.

12.

Nicotine as a potential neuroprotective agent for Parkinson's disease.

Quik M, Perez XA, Bordia T.

Mov Disord. 2012 Jul;27(8):947-57. doi: 10.1002/mds.25028. Epub 2012 Jun 12. Review.

13.

Premotor Parkinson's disease: concepts and definitions.

Siderowf A, Lang AE.

Mov Disord. 2012 Apr 15;27(5):608-16. doi: 10.1002/mds.24954.

14.

Environmental tobacco smoke and Parkinson's disease.

Searles Nielsen S, Gallagher LG, Lundin JI, Longstreth WT Jr, Smith-Weller T, Franklin GM, Swanson PD, Checkoway H.

Mov Disord. 2012 Feb;27(2):293-6. doi: 10.1002/mds.24012. Epub 2011 Nov 16.

15.

Solvent exposures and Parkinson disease risk in twins.

Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM.

Ann Neurol. 2012 Jun;71(6):776-84. doi: 10.1002/ana.22629. Epub 2011 Nov 14.

16.

Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses.

Miwa JM, Freedman R, Lester HA.

Neuron. 2011 Apr 14;70(1):20-33. doi: 10.1016/j.neuron.2011.03.014. Review.

17.

An exploratory study on the CHRNA3-CHRNA5-CHRNB4 cluster, smoking, and Parkinson's disease.

Gao J, Xu H, Weinberg C, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, Burch L, Chen H.

Neurodegener Dis. 2011;8(5):296-9. doi: 10.1159/000323190. Epub 2011 Jan 13.

18.

Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Lin W, Kang UJ.

J Clin Neurol. 2005 Oct;1(2):107-20. doi: 10.3988/jcn.2005.1.2.107. Epub 2005 Oct 20.

19.

Smoking duration, intensity, and risk of Parkinson disease.

Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A.

Neurology. 2010 Mar 16;74(11):878-84. doi: 10.1212/WNL.0b013e3181d55f38. Epub 2010 Mar 10.

20.

Multiple roles for nicotine in Parkinson's disease.

Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA.

Biochem Pharmacol. 2009 Oct 1;78(7):677-85. doi: 10.1016/j.bcp.2009.05.003. Epub 2009 May 9. Review.

Supplemental Content

Support Center